Multiple Myeloma Clinical Practice Guidelines in OncologyNCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.OverviewMultiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. The American Cancer Society estimates that 20,580 new cases of MM will occur in the United States in 2009, including 11,680 in men and 8900 in women, with an estimated 10,580 deaths.1 The mean age of affected individuals is 62 years for men (75% > 70 years) and 61 years for women (79% > 70 years). The treatment of MM has dramatically improved over the past decade. The 5-year survival rate reported in the Surveillance Epidemiology and End Results database has increased from 25% in 1975 to 34% in 2003 because of the availability of newer and more effective treatment options.2,3MM is typically sensitive to various cytotoxic drugs, both as initial treatment...

If the inline PDF is not rendering correctly, you can download the PDF file here.

References

  • 1

    JemalASiegelRWardE. Cancer statistics, 2009. CA Cancer J Clin2009;59:225249.

  • 2

    BrennerHGondosAPulteD. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood2008;111:25212526.

    • Search Google Scholar
    • Export Citation
  • 3

    KumarSKRajkumarSVDispenzieriA. Improved survival in multiple myeloma and the impact of novel therapies. Blood2008;111:25162520.

  • 4

    HideshimaTAndersonKC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer2002;2:927937.

  • 5

    KyleRAGertzMAWitzigTE. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc2003;78:2133.

  • 6

    FonsecaRBarlogieBBatailleR. Genetics and cytogenetics of multiple myeloma: a Workshop Report. Cancer Res2004;64:15461558.

  • 7

    DewaldGWTherneauTLarsonD. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood2005;106:35533558.

    • Search Google Scholar
    • Export Citation
  • 8

    MoulopoulosLADimopoulosMAWeberD. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. J Clin Oncol1993;11:13111315.

    • Search Google Scholar
    • Export Citation
  • 9

    DurieBGWaxmanADD’AgnoloAWilliamsCM. Whole-body (18)F-FDG PET identifies high-risk myeloma. J Nucl Med2002;43:14571463.

  • 10

    SchirrmeisterHBommerMBuckAK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging2002;29:361366.

    • Search Google Scholar
    • Export Citation
  • 11

    DispenzieriAKyleRMerliniG. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia2009;23:215224.

    • Search Google Scholar
    • Export Citation
  • 12

    TateJRGillDCobcroftRHickmanPE. Practical considerations for the measurement of free light chains in serum. Clin Chem2003;49:12521257.

    • Search Google Scholar
    • Export Citation
  • 13

    BradwellARCarr-SmithHDMeadGP. Serum test for assessment of patients with Bence Jones myeloma. Lancet2003;361:489491.

  • 14

    GreippPLustJO’FallonM. Plasma cell labeling index and B2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood1993;81:33823387.

    • Search Google Scholar
    • Export Citation
  • 15

    GreippPSan MiquelJDurieB. International staging system for multiple myeloma. J Clin Oncol2005;23:34123420.

  • 16

    KnowlingMAHarwoodARBergsagelDE. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. J Clin Oncol1983;1:255262.

    • Search Google Scholar
    • Export Citation
  • 17

    DimopoulosMAGoldsteinJFullerL. Curability of solitary bone plasmacytoma. J Clin Oncol1992;10:587590.

  • 18

    HuKYahalomJ. Radiotherapy in the management of plasma cell tumors. Oncology2000;14:101111.

  • 19

    KatoTTsukamotoENishiokaT. Early detection of bone marrow involvement in extramedullary plasmacytoma by whole-body F-18 FDG positron emission tomography. Clin Nucl Med2000;25:870873.

    • Search Google Scholar
    • Export Citation
  • 20

    SchirrmeisterHBommerMBuckAK. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging2002;29:361366.

    • Search Google Scholar
    • Export Citation
  • 21

    JadvarHContiPS. Diagnostic utility of FDG PET in multiple myeloma. Skeletal Radiol2002;31:690694.

  • 22

    OrchardKBarringtonSBuscombeJ. Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma. Br J Haematol2002;117:133135.

    • Search Google Scholar
    • Export Citation
  • 23

    SchirrmeisterHBuckAKBergmannL. Positron emission tomography (PET) for staging of solitary plasmacytoma. Cancer Biother Radiopharm2003;8:841845.

    • Search Google Scholar
    • Export Citation
  • 24

    BredellaMASteinbachLCaputoG. Value of FDG PET in the assessment of patients with multiple myeloma. Am J Roentgenol2005;184:11991204.

    • Search Google Scholar
    • Export Citation
  • 25

    HarousseauJLMathiotCAttalM. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J Clin Oncol2008;26(Suppl 15):Abstract 8505.

    • Search Google Scholar
    • Export Citation
  • 26

    SonneveldPvan der HoltBSchmidt-WolfIGH. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycin, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood2008;112:243a. Abstract 653.

    • Search Google Scholar
    • Export Citation
  • 27

    CavoMTacchettiPPatriarcaF. Superior complete response rate and progression-free survival after autologous transplantation with up-front Velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Blood2008;112:Abstract 158.

    • Search Google Scholar
    • Export Citation
  • 28

    RichardsonPJagannathSRajeN. Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) as front-line therapy for patients with multiple myeloma (MM): preliminary results of a phase II study [abstract]. Blood2007;110:Abstract 187.

    • Search Google Scholar
    • Export Citation
  • 29

    RichardsonPLonialSJakubowiakA. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study [abstract]. Blood2008;112:Abstract 92.

    • Search Google Scholar
    • Export Citation
  • 30

    RichardsonPGSonneveldPSchusterMW. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med2005;352:24872498.

    • Search Google Scholar
    • Export Citation
  • 31

    MateosMVHernandezJMHernandezMT. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 trial. Blood2006;108:21652172.

    • Search Google Scholar
    • Export Citation
  • 32

    ZonderAJCrowleyJHusseinM. Superiority of lenalidomide (Len) plus high-dose Dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232 [abstract]. Blood2007;110:Abstract 77.

    • Search Google Scholar
    • Export Citation
  • 33

    RajkumarSVJacobusSCallanderN. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood2006;108:Abstract 799.

    • Search Google Scholar
    • Export Citation
  • 34

    RajkumarSVJacobusSCallanderN. Randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood2007;110:Abstract 74.

    • Search Google Scholar
    • Export Citation
  • 35

    ParipatiHStewartAKCabouS. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia2008;22:12821284.

    • Search Google Scholar
    • Export Citation
  • 36

    KumarSDispenzieriALacyMQ. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia2007;21:20352042.

    • Search Google Scholar
    • Export Citation
  • 37

    MazumderAKaufmanJNiesvizkyR. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia2008;22:12801281.

    • Search Google Scholar
    • Export Citation
  • 38

    PalumboARajkumarSVDimopoulosMA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia2008;22:414423.

    • Search Google Scholar
    • Export Citation
  • 39

    RajkumarSVBloodEVesoleD. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol2006;24:431436.

    • Search Google Scholar
    • Export Citation
  • 40

    RifkinRMGregorySAMohrbacherAHusseinMA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer2006;106:848858.

    • Search Google Scholar
    • Export Citation
  • 41

    GregoryWMRichardsMAMalpasJS. Combination chemotherapy vs. melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol1992;10:334342.

    • Search Google Scholar
    • Export Citation
  • 42

    PalumboABringhenSCaravitaT. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet2006;367:825831.

    • Search Google Scholar
    • Export Citation
  • 43

    FaconTMaryJYHulinC. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet2007;370:12091218.

    • Search Google Scholar
    • Export Citation
  • 44

    HulinCFaconTRodonP. Melphalan- prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients 75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01 [abstract]. Blood2007;110:Abstract 75

    • Search Google Scholar
    • Export Citation
  • 45

    WaageAGimsingPJuliussonG. Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase III trial [abstract]. Blood2007;110: Abstract 78.

    • Search Google Scholar
    • Export Citation
  • 46

    PalumboABringhenSLiberatiAM. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood2008;112:31073114.

    • Search Google Scholar
    • Export Citation
  • 47

    WijermansPSchaafsmaMvan NordenY. Melphalan + prednisone versus melphalan + prednisone + thalidomide induction therapy for multiple myeloma in elderly patients: first interim results of the Dutch cooperative group HOVON [abstract]. Haematologica2008;93:Abstract 178.

    • Search Google Scholar
    • Export Citation
  • 48

    San MiguelJFSchlagRKhuagevaNK. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med2008;359:906917.

    • Search Google Scholar
    • Export Citation
  • 49

    MiguelJFSSchlagRKhuagevaNK. Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma [abstract]. Blood2008;112:Abstract 650.

    • Search Google Scholar
    • Export Citation
  • 50

    BadrosABarlogieBMorrisC. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood2001;97:25742579.

    • Search Google Scholar
    • Export Citation
  • 51

    KrogerNSchwerdtfegerRKiehlM. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood2002;100:755760.

    • Search Google Scholar
    • Export Citation
  • 52

    MaloneyDSahebiFStockerl-GoldsteinKE. Combining an allogenic graft versus myeloma effect with high dose autologous stem cell rescue in the treatment of multiple myeloma [abstract]. Blood2001;98:Abstract 434a.

    • Search Google Scholar
    • Export Citation
  • 53

    MoreauPFaconTAttalM. Intergroupe Francophone du Myelome. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood2002;99:731735.

    • Search Google Scholar
    • Export Citation
  • 54

    AttalMHarousseauJLStoppaAM. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med1996;335:9197.

    • Search Google Scholar
    • Export Citation
  • 55

    ChildJAMorganGJDaviesFE. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med2003;348:18751883.

    • Search Google Scholar
    • Export Citation
  • 56

    BarlogieBKyleRAAndersonKC. Standard chemotherapy compared with high dose chemoradiotherapy for multiple myeloma. Final results of phase III US Intergroup Trial S9321. J Clin Oncol2006;24:929936.

    • Search Google Scholar
    • Export Citation
  • 57

    FermandJPKatsahianSDivineM. High dose therapy and autologous blood stem cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol2005;23:92279233.

    • Search Google Scholar
    • Export Citation
  • 58

    CorradiniPCavoMLokhorstH. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myelomaBlood2003;102:19271929.

    • Search Google Scholar
    • Export Citation
  • 59

    KumarSLacyMQDispenzieriA. High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy. Bone Marrow Transplant2004;34:161167.

    • Search Google Scholar
    • Export Citation
  • 60

    HahnTWingardJRAndersonKC. The role of cytotoxic therapy with haematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidenced based review. Biol Blood Marrow Transplant2003;9:437.

    • Search Google Scholar
    • Export Citation
  • 61

    AttalMHarousseauJLFaconT. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med2003;349:24952502.

    • Search Google Scholar
    • Export Citation
  • 62

    StadtmauerEA. Multiple myeloma 2004—one or two transplants?N Engl J Med2003;349:25512553.

  • 63

    FermandJPKatsahianSDevineM. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol2005;23:92279233.

    • Search Google Scholar
    • Export Citation
  • 64

    GoldschmidtH. Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 trial [abstract]. Haematologica2005;90(Suppl 1):Abstract 38.

    • Search Google Scholar
    • Export Citation
  • 65

    SonneveldPvan der HoltBSegerenC. Intensive versus double intensive therapy in untreated multiple myeloma: updated analysis of the randomized phase III study HOVON 24 MM [abstract]. Blood2004;104:Abstract 948.

    • Search Google Scholar
    • Export Citation
  • 66

    CavoMTosiPZamagniE. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 Clinical Study. J Clin Oncol2007;25:24342441.

    • Search Google Scholar
    • Export Citation
  • 67

    KyleRA. High dose therapy in multiple myeloma and primary amyloidosis: an overview. Semin Oncol1999;26:7483.

  • 68

    KumarALoughranTAlsinaM. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol2003;4:293304.

    • Search Google Scholar
    • Export Citation
  • 69

    BrunoBRottaMPatriarcaF. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med2007;356:11101120.

  • 70

    GarbanFAttalMMichalletM. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood2006;107:34743480.

    • Search Google Scholar
    • Export Citation
  • 71

    MaloneyDGMolinaAJSahebiF. Allografting with nonmyeloablative conditioning following cytoreductive autograft for the treatment of patients with multiple myeloma. Blood2003;102:34473454.

    • Search Google Scholar
    • Export Citation
  • 72

    CrawleyCLalancetteMSzydloR. Outcome for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood2005;105:45324539.

    • Search Google Scholar
    • Export Citation
  • 73

    ZeiserRBertzHSpyridonidisA. Donor lymphocyte infusions for multiple myeloma: clinical results and novel perspectives. Bone Marrow Transplant2004;34:923928.

    • Search Google Scholar
    • Export Citation
  • 74

    BrowmanGPBergsagelDSicheriD. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol1995;13:23542360.

    • Search Google Scholar
    • Export Citation
  • 75

    ShustikCBelchARobinsonS. Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinical Trials Group Study: MY.7 [abstract]. J Clin Oncol2004;22(Suppl 14):Abstract 6510.

    • Search Google Scholar
    • Export Citation
  • 76

    FritzELudwigH. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3948 patients. Ann Oncol2000;11:14271436.

    • Search Google Scholar
    • Export Citation
  • 77

    BrinkerBTWallerEKLeongT. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer2006;106:21712180.

    • Search Google Scholar
    • Export Citation
  • 78

    AttalMHarousseauJLLeyvrazS. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood2006;108:32893294.

    • Search Google Scholar
    • Export Citation
  • 79

    SpencerAPrinceMRobertsAW. First analysis of the Australian leukaemia and lymphoma group (ALLG) trial of thalidomide and alternate day prednisone following autologous stem cell transplantation (ASCT) for patients with multiple myeloma (ALLGMM6) [abstract]. Blood2006;108:Abstract 58.

    • Search Google Scholar
    • Export Citation
  • 80

    BarlogieBKyleRAAndersonKC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321. J Clin Oncol2006;24:929936.

    • Search Google Scholar
    • Export Citation
  • 81

    BarlogieBTricotGAnaissieE. Thalidomide and hematopoietic cell transplantation for multiple myeloma. N Eng J Med2006;354:10211030.

  • 82

    RichardsonPSonneveldPSchusterM. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood2007;110:35573560.

    • Search Google Scholar
    • Export Citation
  • 83

    JagannathSRichardsonPGSonneveldP. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia2007;21:151157.

    • Search Google Scholar
    • Export Citation
  • 84

    OrlowskiRZNaglerASonneveldP. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol2007;25:38923901.

    • Search Google Scholar
    • Export Citation
  • 85

    WeberDMChenCNiesvizkyR. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med2007;357:21332142.

    • Search Google Scholar
    • Export Citation
  • 86

    DimopoulosMSpencerAAttalM. Lenalidomide plus dexamethasone for relapsed or refractory multiple myelomaN Engl J Med2007;357:21232132.

    • Search Google Scholar
    • Export Citation
  • 87

    RichardsonPJagannathSHusseinM. A muticenter, single arm, open label study to evaluate the efficacy and safety of single agent lenalidomide in patients with relapsed and refractory multiple myeloma [abstract]. Blood2005;106:Abstract 2550.

    • Search Google Scholar
    • Export Citation
  • 88

    RajkumarSVFonsecaRDispenzieriA. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc2000;75:897901.

  • 89

    LeeCKBarlogieBMunshiN. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol2003;21:27322739.

    • Search Google Scholar
    • Export Citation
  • 90

    SinghalSMehtaJDesikanR. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med1999;341:15651571.

  • 91

    WaageAGimsingPJuliussonG. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. Br J Haematology2004;125:149155.

    • Search Google Scholar
    • Export Citation
  • 92

    MohtyMAttalMMaritG. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Society Francaise de Greffe de Moelle et Therapie Cellulairs (SFGM-TC). Bone Marrow Transplant2005;35:165169.

    • Search Google Scholar
    • Export Citation
  • 93

    KnopSStrakaCHaenM. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica2005;90:12871288.

    • Search Google Scholar
    • Export Citation
  • 94

    RichardsonPJagannathSAviganDE. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial [abstract]. Blood2006;108:Abstract 405.

    • Search Google Scholar
    • Export Citation
  • 95

    AndersonKCJagannathSJakubowiakA. Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM) [abstract]. J Clin Oncol2008;26(Suppl 15):Abstract 8545.

    • Search Google Scholar
    • Export Citation
  • 96

    IkhlaqueNSeshadriVKathulaSBaumannMA. Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. Am J Hematol2006;81:420422.

    • Search Google Scholar
    • Export Citation
  • 97

    BazRLiLKottke-MarchantK. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc2005;80:15681574.

    • Search Google Scholar
    • Export Citation
  • 98

    BerensonJRLichtensteinAPorterL. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med1996;334:488493.

    • Search Google Scholar
    • Export Citation
  • 99

    BerensonJRLichtensteinAPorterL. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol1998;16:593602.

    • Search Google Scholar
    • Export Citation
  • 100

    MajorPLortholaryAHonJ. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol2001;19:558567.

    • Search Google Scholar
    • Export Citation
  • 101

    BloomfieldDJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol1998;16:12181225.

    • Search Google Scholar
    • Export Citation
  • 102

    KyleRAYeeGCSomerfieldMR. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol2007;25:24642472.

    • Search Google Scholar
    • Export Citation
  • 103

    ZervasKVerrouETeleioudisZ. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol2006;134:620623.

    • Search Google Scholar
    • Export Citation
  • 104

    LindsleyHTellerDNoonanB. Hyperviscosity syndrome in multiple myeloma. A reversible, concentration-dependent aggregation of the myeloma protein. Am J Med1973;54:682688.

    • Search Google Scholar
    • Export Citation
  • 105

    LudwigHFritzEKotzmannH. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med1990;322:16931699.

  • 106

    OsterborgABoogaertsMACiminoR. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma—a randomized multicenter study. Blood1996;87:2675682.

    • Search Google Scholar
    • Export Citation
  • 107

    Chanan-KhanASonneveldPSchusterMW. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol2008;26:47844790.

    • Search Google Scholar
    • Export Citation
  • 108

    FalkRHComenzoRLSkinnerM. The systemic amyloidoses: current approaches to diagnosis and treatment. N Engl J Med1997;337:898909.

  • 109

    SkinnerMSanchorawalaVSeldinDC. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med2004;140:8593.

    • Search Google Scholar
    • Export Citation
  • 110

    DispenzieriAKyleRALacyMQ. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplant: a case control study. Blood2004;103:39603963.

    • Search Google Scholar
    • Export Citation
  • 111

    GertzMALacyMQDispenzieriA. Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev2004;18:1737.

  • 112

    PalladiniGPerfettiVObiciL. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood2004;103:29362938.

    • Search Google Scholar
    • Export Citation
  • 113

    ComenzoRLGertzMA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood2002;99:42764282.

  • 114

    DhodapkarMVHusseinMARasmussenE. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood2004;104:35203526.

    • Search Google Scholar
    • Export Citation
  • 115

    DispenzieriALacyMQZeldenrustSR. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood2007;109:465470.

    • Search Google Scholar
    • Export Citation
  • 116

    SanchorawalaVWrightDGRosenzweigM. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood2007;109:492496.

    • Search Google Scholar
    • Export Citation
  • 117

    WechalekarADLachmannHJOfferM. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica2008;93:295298.

    • Search Google Scholar
    • Export Citation
  • 118

    DimopoulosMAAlexanianR. Waldenström’s macroglobulinemia. Blood1994;83:14521459.

  • 119

    GhobrialIMGertzMAFonsecaR. Waldenström macroglobulinaemia. Lancet Oncol2003;4:679685.

  • 120

    McIntyreOR. Laboratory investigation of myeloma. In: MalpasJSBergsagelDEKyleRA. eds. Myeloma: Biology and Management. Oxford: Oxford University Press; 1998:217.

    • Search Google Scholar
    • Export Citation
  • 121

    DimopoulosMAKantarjianHEsteyE. Treatment of Waldenström’s macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med1993;118:195198.

    • Search Google Scholar
    • Export Citation
  • 122

    DimopoulosMAZervasCZomasA. Treatment of Waldenstrom’s macroglobulinemia with rituximab. J Clin Oncol2002;20:23272333.

  • 123

    DimopoulosMAZomasAViniouNA. Treatment of Waldenstrom’s macroglobulinemia with thalidomide. J Clin Oncol2001;19:35963601.

  • 124

    ChenCIKouroukisCTWhiteD. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol2007;25:15701575.

    • Search Google Scholar
    • Export Citation
  • 125

    GertzMAAnagnostopoulosAAndersonKC. Treatment recommendations in Waldenström’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström’s Macroglobulinemia. Semin Oncol2003;30:121126.

    • Search Google Scholar
    • Export Citation
  • 126

    GertzMA. Waldenström’s macroglobulinemia: a review of therapy. Leuk Lymphoma2002;43:15171526.

  • 127

    DimopoulosMAGertzMAKastritisE. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom’s Macroglobulinemia. J Clin Oncol2009;27:120126.

    • Search Google Scholar
    • Export Citation
  • 128

    DimopoulosMAKantarjianHWeberD. Primary therapy of Waldenström’s macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol1994;2:26942698.

    • Search Google Scholar
    • Export Citation
  • 129

    ForanJMRohatinerAZCoiffierB. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom’s macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol1999;17:546553.

    • Search Google Scholar
    • Export Citation
  • 130

    DimopoulosMAO’BrienSKantarjianH. Treatment of Waldenstrom’s macroglobulinemia with nucleoside analogues. Leuk Lymphoma1993;11(Suppl 2):105108.

    • Search Google Scholar
    • Export Citation
  • 131

    TreonSPAgusDBLinkB. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström’s macroglobulinemia. J Immunotherapy2001;24:272279.

    • Search Google Scholar
    • Export Citation

Article Information

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 61 61 16
PDF Downloads 23 23 9
EPUB Downloads 0 0 0